IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis

Osteoarthritis and Cartilage

Volumn 19, Issue 6, 2011, Pages 711-718

  Chen, L ^a   Li, D Q ^b   Zhong, J ^a   Wu, X L ^c   Chen, Q ^a   Peng, H ^a   Liu, S Q ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Aptamer; Celecoxib; Cell SELEX; IL 17RA; Osteoarthritis; Synovium inflammation

Indexed keywords

APTAMER; CELECOXIB; DNA; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; RA 10 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HISTOLOGY; IN VITRO STUDY; MENISCECTOMY; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVITIS; SYNOVIUM;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-6; MICE; OSTEOARTHRITIS, KNEE; POLYMERASE CHAIN REACTION; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES; SYNOVIAL MEMBRANE;

EID: 79955955062     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2011.01.018     Document Type: Article

References (34)

1. Honorati M.C., Bovara M., Cattini L., Piacentini A., Facchini A. Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage 2002, 10(10):799-807.
2. Benderdour M., Tardif G., Pelletier J.P., Di Battista J.A., Reboul P., Ranger P., et al. Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. J Rheumatol 2002, 29(6):1262-1272.
3. Honorati M.C., Neri S., Cattini L., Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006, 14(4):345-352.
4. Goldberg M., Nadiv O., Luknar-Gabor N., Agar G., Beer Y., Katz Y. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009, 46(8-9):1854-1859.
5. Janke M., Peine M., Nass A., Morawietz L., Hamann A., Scheffold A. In-vitro-induced Th17 cells fail to induce inflammation in vivo and show an impaired migration into inflamed sites. Eur J Immunol 2010, 40(4):1089-1098.
6. Zrioual S., Toh M.L., Tournadre A., Zhou Y., Cazalis M.A., Pachot A., et al. IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 2008, 180(1):655-663.
7. Maitra A., Shen F., Hanel W., Mossman K., Tocker J., Swart D., et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc Natl Acad Sci U S A 2007, 104(18):7506-7511.
8. Fang X., Tan W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 2010, 43(1):48-57.
9. Sefah K., Shangguan D., Xiong X., O'Donoghue M.B., Tan W. Development of DNA aptamers using cell-SELEX. Nat Protoc 2010, 5(6):1169-1185.
10. Kim Y., Liu C., Tan W. Aptamers generated by cell SELEX for biomarker discovery. Biomark Med 2009, 3(2):193-202.
11. Zhou Y., Toh M.L., Zrioual S., Miossec P. IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine 2007, 38(3):157-164.
12. Li D., Li Y., Wu X., Li Q., Yu J., Gen J., et al. Knockdown of Mgat5 inhibits breast cancer cell growth with activation of CD4+ T cells and macrophages. J Immunol 2008, 180(5):3158-3165.
13. Pan Q., Zhang X.L., Wu H.Y., He P.W., Wang F., Zhang M.S., et al. Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi. Antimicrob Agents Chemother 2005, 49(10):4052-4060.
14. Kamekura S., Hoshi K., Shimoaka T., Chung U., Chikuda H., Yamada T., et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage 2005, 13:632-641.
15. Shangguan D., Li Y., Tang Z., Cao Z.C., Chen H.W., Mallikaratchy P., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103(32):11838-11843.
16. Loeuille D., Chary-Valckenaere I., Champigneulle J., Rat A.C., Toussaint F., Pinzano-Watrin A., et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum 2005, 52(11):3492-3501.
17. Agarwal S., Misra R., Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008, 35(3):515-519.
18. Taketa T., Sakai A., Tanaka S., Nakai K., Menuki K., Yamane H., et al. Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells. J Bone Miner Metab 2008, 26(2):143-151.
19. Tipton D.A., Flynn J.C., Stein S.H., Dabbous MKh Cyclooxygenase-2 inhibitors decrease interleukin-1beta-stimulated prostaglandin E2 and IL-6 production by human gingival fibroblasts. J Periodontol 2003, 74(12):1754-1763.
20. Bukata S.V., Gelinas J., Wei X., Rosier R.N., Puzas J.E., Zhang X., et al. PGE2 and IL-6 production by fibroblasts in response to titanium wear debris particles is mediated through a Cox-2 dependent pathway. J Orthop Res 2004, 22(1):6-12.
21. Li X., Yuan F.L., Lu W.G., Zhao Y.Q., Li C.W., Li J.P., et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 2010 Jun 25, 397(2):131-135.
22. Yu J.J., Ruddy M.J., Wong G.C., Sfintescu C., Baker P.J., Smith J.B., et al. An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 2007, 109(9):3794-3802.
23. Smith E., Stark M.A., Zarbock A., Burcin T.L., Bruce A.C., Vaswani D., et al. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through " short-loop" inhibition via IL-17 receptor. J Immunol 2008, 181(2):1357-1364.
24. Lubberts E., Koenders M.I., van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7(1):29-37.
25. Koenders M.I., Lubberts E., van de Loo F.A., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006, 176(10):6262-6269.
26. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Kolls J.K., et al. Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1. Arthritis Rheum 2005, 52(3):975-983.
27. Malemud C.J. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging 2010, 27(2):95-115.
28. Yang K.G., Raijmakers N.J., van Arkel E.R., Caron J.J., Rijk P.C., Willems W.J., et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomised controlled trial. Osteoarthritis Cartilage 2008, 16(4):498-505.
29. Chabaud M., Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001, 44(6):1293-1303.
30. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Di Padova F.E., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005, 167(1):141-149.
31. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009, 86(3):151-164.
32. Emerson M.V., Lauer A.K. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007, 21(4):245-257.
33. Chabaud M., Fossiez F., Taupin J.L., Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998, 161:409-414.
34. Cheung P.F., Wong C.K., Lam C.W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 2008, 180(8):5625-5635.